Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD8-M5258 | Mouse | Mouse CD28 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
CD8-M82E3 | Mouse | Biotinylated Mouse CD28 Protein, His,Avitag™, active dimer (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD8-H82E5 | Human / Cynomolgus / Rhesus macaque | Biotinylated Human / Cynomolgus / Rhesus macaque CD28 Protein, His,Avitag™, active dimer (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD8-H52Hc | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, His Tag, active dimer (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD8-H525a | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, Fc Tag, active dimer (MALS verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
CD8-H52A5 | Human / Cynomolgus / Rhesus macaque | Human / Cynomolgus / Rhesus macaque CD28 Protein, Mouse IgG2a Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD8-H82F2 | Human / Cynomolgus / Rhesus macaque | Biotinylated Human / Cynomolgus / Rhesus macaque CD28 Protein, Fc,Avitag™, active dimer (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD8-M52H6 | Mouse | Mouse CD28 Protein, His Tag, active dimer (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
Lulizumab pegol | Lulizumab; BMS-931699 | Phase 2 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome | Details |
Theralizumab | TAB-08; TABO-8 | Phase 2 Clinical | Theramab | Solid tumours; Carcinoma, Merkel Cell; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Psoriasis | Details |
Reltecimod | P2-TA; AB-103 | Phase 3 Clinical | Atox Bio | Peritonitis; Acute Kidney Injury; Fournier Gangrene; Fasciitis, Necrotizing; Soft Tissue Infections | Details |
B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
SAR-443216(Sanofi) | SAR-443216 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics | Solid tumours | Details |
ALPN-202 | ALPN-202 | Phase 1 Clinical | Alpine Immune Sciences | Solid tumours; Lymphoma | Details |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Psioxus Therapeutics Ltd | Neoplasms | Details |
InHeAb-01 | InHeAb-01; bsAB | Clinical | Neoplasms | Details | |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences, Abbvie Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
REGN-5668 | REGN-5668 | Phase 2 Clinical | Regeneron Pharmaceuticals | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals | Solid tumours | Details |
REGN-5678 | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms | Details |
FR-104 | FR-104; JNJ-3133; VEL-101 | Phase 2 Clinical | Effimune | Arthritis, Rheumatoid; Rejection of organ transplantation; Postoperative Complications | Details |
This web search service is supported by Google Inc.